Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Thomas PowlesJames W F CattoMatthew D GalskyHikmat A Al-AhmadieJoshua J MeeksHiroyuki NishiyamaToan Quang VuLorenzo AntonuzzoPawel WiechnoVagif AtduevAriel Galapo KannTae-Hwan KimCristina SuárezChao-Hsiang ChangFlorian RoghmannMustafa ÖzgüroğluBernhard J EiglNiara OliveiraTomas BuchlerMoran GadotYousef ZakhariaJon ArmstrongAshok GuptaStephan HoisMichiel S van der Heijdennull nullPublished in: The New England journal of medicine (2024)
Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).